Anrun Pharmaceutical Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • PE Growth

  • Financing Rounds
  • 3

Anrun Pharmaceutical General Information

Description

Developer of drugs designed for anti-tumor, cardiovascular, central nervous system, anti-infection and other fields of therapeutic drugs and generic drug synthesis process. The company provides innovative discovery services of new drugs and new clinical candidate identification enabling domestic and foreign enterprise to receive high-quality APIs and key intermediates.

Contact Information

Website
www.arromax.com
Formerly Known As
Suzhou Anrui Pharmaceutical Co., Ltd.
Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Corporate Office
  • BIdg 6,No.1 Huayun Road
  • Sangtiandao Science Innovation Park
  • Suzhou, Jiangsu 215123
  • China
+86 159
Primary Industry
Drug Discovery
Corporate Office
  • BIdg 6,No.1 Huayun Road
  • Sangtiandao Science Innovation Park
  • Suzhou, Jiangsu 215123
  • China
+86 159

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Anrun Pharmaceutical Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Anrun Pharmaceutical‘s full profile, request access.

Request a free trial

Anrun Pharmaceutical Patents

Anrun Pharmaceutical Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026036924-A1 Pharmaceutically acceptable salt of tyrosine kinase inhibitor, crystal, preparation method, and use Pending 16-Aug-2024
WO-2025223193-A1 Amide derivative as sodium channel modulator and use thereof Pending 23-Apr-2024
EP-4299575-A1 Btk and/or btk c481s small molecule inhibitor and use thereof Pending 26-Feb-2021
EP-4299575-A4 Btk and/or btk c481s small molecule inhibitor and use thereof Pending 26-Feb-2021
WO-2022179238-A1 Btk and/or btk c481s small molecule inhibitor and use thereof Inactive 26-Feb-2021 C07D471/04
To view Anrun Pharmaceutical’s complete patent history, request access »

Anrun Pharmaceutical Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Anrun Pharmaceutical‘s full profile, request access.

Request a free trial

Anrun Pharmaceutical FAQs

  • When was Anrun Pharmaceutical founded?

    Anrun Pharmaceutical was founded in 2011.

  • Where is Anrun Pharmaceutical headquartered?

    Anrun Pharmaceutical is headquartered in Suzhou, China.

  • What industry is Anrun Pharmaceutical in?

    Anrun Pharmaceutical’s primary industry is Drug Discovery.

  • Is Anrun Pharmaceutical a private or public company?

    Anrun Pharmaceutical is a Private company.

  • What is Anrun Pharmaceutical’s current revenue?

    The current revenue for Anrun Pharmaceutical is .

  • How much funding has Anrun Pharmaceutical raised over time?

    Anrun Pharmaceutical has raised $941K.

  • Who are Anrun Pharmaceutical’s investors?

    Crown Asia Investment, Shenzhen Qianhai Lanwan Investment Management, Chang'an Capital, and Danen Capital have invested in Anrun Pharmaceutical.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process